Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123623952 | 12362395 | 2 | F | 20160711 | 20160512 | 20160801 | PER | US-PFIZER INC-2016225721 | PFIZER | 60.00 | YR | F | Y | 73.00000 | KG | 20160801 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123623952 | 12362395 | 1 | PS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 300 MG, 3X/DAY BY MOUTH | N | 20235 | 300 | MG | CAPSULE, HARD | TID | |||||
| 123623952 | 12362395 | 2 | SS | GABAPENTIN. | GABAPENTIN | 1 | 300 MG, UNK | N | 20235 | 300 | MG | CAPSULE, HARD | |||||||
| 123623952 | 12362395 | 3 | C | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 800 MG, 1X/DAY BY MOUTH AT NIGHT | 0 | 800 | MG | TABLET | QD | ||||||
| 123623952 | 12362395 | 4 | C | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | 0 | TABLET | |||||||||||
| 123623952 | 12362395 | 5 | C | TEMAZEPAM. | TEMAZEPAM | 1 | Oral | 30 MG, 1X/DAY BY MOUTH | 0 | 30 | MG | TABLET | QD | ||||||
| 123623952 | 12362395 | 6 | C | FLUOXETINE | FLUOXETINE HYDROCHLORIDE | 1 | Oral | 20 MG, 1X/DAY BY MOUTH | 0 | 20 | MG | TABLET | QD | ||||||
| 123623952 | 12362395 | 7 | C | LAMOTRIGINE. | LAMOTRIGINE | 1 | Oral | 200 MG, 1X/DAY BY MOUTH | 0 | 200 | MG | CAPSULE | QD | ||||||
| 123623952 | 12362395 | 8 | C | SIMVASTATIN. | SIMVASTATIN | 1 | Oral | 40 MG, 1X/DAY BY MOUTH AT NIGHT | 0 | 40 | MG | QD | |||||||
| 123623952 | 12362395 | 9 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | Oral | 25 MG, 1X/DAY BY MOUTH | 0 | 25 | MG | TABLET | QD | ||||||
| 123623952 | 12362395 | 10 | C | CLONAZEPAM. | CLONAZEPAM | 1 | Oral | 0.5 MG, AS NEEDED BY MOUTH | 0 | .5 | MG | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123623952 | 12362395 | 1 | Neuropathy peripheral |
| 123623952 | 12362395 | 2 | Back pain |
| 123623952 | 12362395 | 3 | Anxiety |
| 123623952 | 12362395 | 4 | Insomnia |
| 123623952 | 12362395 | 5 | Insomnia |
| 123623952 | 12362395 | 6 | Anxiety |
| 123623952 | 12362395 | 7 | Anxiety |
| 123623952 | 12362395 | 8 | Blood cholesterol abnormal |
| 123623952 | 12362395 | 9 | Hypertension |
| 123623952 | 12362395 | 10 | Anxiety |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123623952 | 12362395 | Drug ineffective for unapproved indication |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 123623952 | 12362395 | 1 | 20160411 | 0 |